NCT07204080尚未招募2 期
Phase II Clinical Trial Evaluating the Safety Efficacy of Fc-Modified Anti-CD154 mAB (TNX-1500) in Kidney Transplant Recipients
Ayman Al Jurdi, MD1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2026年11月1日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Number of Adverse Events in each subject
研究概览
简要总结
The primary objective is to investigate the safety of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects ≥18 to 75 years of age.
- •Kidney transplant candidates with chronic kidney disease (stage IV or V) or end-stage kidney disease evaluated and listed for transplantation at Massachusetts General Hospital.
- •Recipient of an ABO-compatible, non-human leukocyte antigen (HLA) identical living or deceased donor kidney (de novo)
- •Ability to understand the study requirements and provide written informed consent.
- •Epstein-Barr virus (EBV) seropositive
排除标准
- •Recipient seropositive for human immunodeficiency virus (HIV-1), or hepatitis B surface antigen (HBsAg) or core antibody (Anti-HBc); subjects who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response (SVR) after anti-HCV treatment or spontaneous clearance.
- •Recipient of a kidney from a donor who tests positive for HIV, HBsAg, Anti-HBc, or HCV NAT.
- •Subjects with a severe systemic infection, current or within the 2 weeks prior to screening.
- •Left ventricular ejection fraction < 40% as determined by TTE or clinical evidence of heart failure.
- •Any of the following ocular history or ocular findings at screening exam:
- •Active inflammation in either or both eyes (does not include pigment cell in the AC after dilation); must be greater than trace cell or trace flare to exclude.
- •Findings that would impact the ability to monitor, diagnose, manage, and follow new onset ocular inflammation.
- •Receipt of ocular corticosteroids (topically, intravitreally, or periocularly) or has been treated with anti-VEGF intravitreal therapy within three months of Screening Exam
- •Pregnant or nursing (lactating) women confirmed by human chorionic gonadotropin (hCG) laboratory test.
- •Women of childbearing potential (women capable of becoming pregnant) unless using a highly effective method of contraception during dosing and for 24 weeks after study treatment. Highly effective contraception methods include:
- •Female sterilization (surgical, bilateral oophorectomy with or without hysterectomy), or tubal ligation at least 6 weeks before taking study treatment.
- •Male sterilization (at least 6 months prior to screening); for female subjects on the study, the vasectomized male partners should be the sole partners for that subject.
- •Use of injected or implanted hormonal methods of contraception or other hormonal contraception that have comparable efficacy (<1% for example, hormone vaginal ring or placement of a long-acting reversible contraceptives, an intrauterine device, or intrauterine system.
- •Total abstinence
- •Use of other investigational products or enrollment in another investigational drug study within 30 days prior to screening or 5 half-lives, whichever is longer.
- •Subjects with clinically significant lab abnormalities (>2.5 x the upper limit of normal (ULN) of the following liver function chemistries unless due to, as judged by the investigator, a benign underlying condition:
- •Alanine aminotransferase (ALT)
- •Aspartate aminotransferase (AST)
- •Alkaline phosphatase (ALP)
- •Coagulation studies (international normalization ratio (INR), prothrombin time (PT), and partial thromboplastin time (PTT))
- •Any other clinically significant medical condition, active infection, laboratory abnormality, or psychosocial condition (e.g. history of substance use disorder) that would, in the judgement of the investigator, impact the subject's ability to participate in the trial.
- •Presence of pre-existing donor-specific antibodies (DSA) or calculated panel reactive antibodies (cPRA) >20% based upon results within 6 months prior to transplant.
- •Virtual crossmatch (VXM) positive transplant with an MFI >1000 as assessed by routine methodology (Luminex)
- •Cytomegalovirus (CMV) high risk combination: donor positive to recipient negative
- •Multi-organ transplant or tissue recipient.
- •History of malignancy of any organ system, except for localized excised non-melanomatous skin or carcinoma in situ of the cervix
- •Subjects with any of the following: hemoglobin <8 mg/dL, white blood cell ≤2,000/mm3, or platelet count ≤75,000/mm3.
研究组 & 干预措施
Kidney Transplant Recipient
Experimental
干预措施: Kidney Transplant (Procedure)
Kidney Transplant Recipient
Experimental
干预措施: TNX-1500 (Drug)
结局指标
主要结局
Number of Adverse Events in each subject
时间窗: 12 Months
The primary endpoint is the cumulative incidence of all AEs and SAEs in subjects treated with TNX-1500 at 12-months (Day 364, Week 52).
Number of Serious Adverse Events in each subject
时间窗: 12 Months
The primary endpoint is the cumulative incidence of all AEs and SAEs in subjects treated with TNX-1500 at 12-months (Day 364, Week 52).
次要结局
- Incidence of Biopsy Proven Acute Rejection(12 months)
- Incidence of treatment for acute rejection(12 Months)
- Incidence of de novo DSA development(Months 1, 3, 6, 9, 12)
- GFR measurement(12 months)
- Incidence of graft loss(12 months)
- Incidence of serious opportunistic infections(12 months)
- Incidence of malignancies(12 months)
- Incidence of AEs of Special Interest(12 months)
- Degree of albuminuria(12 Months)
- Incidence of Biopsy Proven Acute Rejection(12 months)
- Incidence of treatment for acute rejection(12 Months)
- Incidence of de novo DSA development(Months 1, 3, 6, 9, 12)
- Incidence of serious opportunistic infections and malignancies(12 months)
- GFR measurement(12 months)
- Incidence of death(12 months)
- Incidence of graft loss(12 months)
- Degree of Proteinuria(12 Months)
研究者
Ayman Al Jurdi, MD
Physician
Massachusetts General Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesGastrointestinal Tract MalignanciesNCT05329766Arcus Biosciences, Inc.332
招募中
1 期
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple MyelomaSmoldering Multiple MyelomaMultiple MyelomaNCT05841550Oslo University Hospital20
终止
2 期
ATX-101 in Advanced Dedifferentiated Liposarcoma and LeiomyosarcomaLeiomyosarcomaLiposarcomaNCT05116683Benjamin Izar4
已完成
1 期
A Multiple Ascending Dose Trial of CVL-231 in Subjects With SchizophreniaSchizophreniaNCT04136873Cerevel Therapeutics, LLC130
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of SchizophreniaNegative Symptoms in SchizophreniaNCT06107803Minerva Neurosciences17